slide1 l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
AMYLIN PHARMACEUTICALS (AMLN) amylin Recent stock price: 21.87 (1/19/04 close) 52-week range: 13.73- 30.75 Market c PowerPoint Presentation
Download Presentation
AMYLIN PHARMACEUTICALS (AMLN) amylin Recent stock price: 21.87 (1/19/04 close) 52-week range: 13.73- 30.75 Market c

Loading in 2 Seconds...

play fullscreen
1 / 4

AMYLIN PHARMACEUTICALS (AMLN) amylin Recent stock price: 21.87 (1/19/04 close) 52-week range: 13.73- 30.75 Market c - PowerPoint PPT Presentation


  • 409 Views
  • Uploaded on

AMYLIN PHARMACEUTICALS (AMLN) www.amylin.com Recent stock price: 21.87 (1/19/04 close) 52-week range: 13.73- 30.75 Market cap: 2.04 Bil Revenue: $13 Mil Expenses: ($119) Mil Net Loss: ($109) Mil P/E: N/A EPS: -1.51 Estimated target price: 27.3

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'AMYLIN PHARMACEUTICALS (AMLN) amylin Recent stock price: 21.87 (1/19/04 close) 52-week range: 13.73- 30.75 Market c' - albert


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

AMYLIN PHARMACEUTICALS (AMLN)www.amylin.com

Recent stock price: 21.87 (1/19/04 close)

52-week range: 13.73- 30.75

Market cap: 2.04 Bil

Revenue: $13 Mil

Expenses: ($119) Mil

Net Loss: ($109) Mil

P/E: N/A EPS: -1.51

Estimated target price: 27.3

Amylin Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative medicines to improve the lives of people with metabolic diseases.

Estimated 177 Mil people worldwide suffer from diabetes, 18 Mil of which have type I diabetes (juvenile, autoimmune), and 159 Mil have type 2 (adult). Approx. 11.5 Mil in U.S. have diabetes, with 1 Mil new cases each year.

10-Q 8K pos. results invest

for Exenatide@ 25

SEC

Exenatide PIII results reported

slide2

Amylin announces SEC investigation of conf. call violation of Regulation FD

GS conf. Call:

Amylin CEO discusses FDA rejection of Symlin

Club Biomed buys 200 shrs AMLN

@ ~ 25

Amylin announces positive P-III results for Exenatide

slide3

January 2003-2004

AMLN

v

AMEX BIOTECH INDEX

AMLN

v

NASDAQ BIOTECH INDEX

slide4

PATENTS

Hold 36 U.S. Patents and 33 pending U.S. patent applications:

17 issued to development and commercialization of SYMLIN (10 pending)

1 issued to development and commercialization of EXENATIDE (15 pending)

Includes SYMLIN and amylin analogs or agonists, methods of synthesis for these molecules, methods of preparing these products, BUT DO NOT have composition-of-matter patent for EXENATIDE or EXENATIDE LAR.